Previous 10 | Next 10 |
Gainers: Novan (NOVN) +74%.Urban One (UONE) +39%.Iconix Brand (ICON) +28%.Aptinyx (APTX) +24%.Carver Bancorp (CARV) +22%.Vaxart (VXRT) +21%.Xinyuan Real Estate (XIN) +20%Broadway Financial (BYFC) +18%.Amesite (AMST) +18%.Siebert Financial (SIEB) +16%.Losers: Recon Technolo...
Penny Stocks That Turned Heads Over The Last 52 Weeks When it comes to finding penny stocks to buy , everyone has the same goal. Naturally, that goal is to make money and repeat the process. But with so many 1 and 2-day breakouts captivating the attention of retail traders, itȁ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Vertex Pharma (NASDAQ: VRTX ) stock is dropping on Friday following the release of results from a Phase 2 clinical trial. Source: Shutterstock That trial was testing the effectiveness of VX-864 . This is a po...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Novan (NASDAQ: NOVN ) stock is soaring today off of some big news. It appears that the company has promising clinical trial results around a common — and quite contagious — skin infection. Novan is ...
Gainers: Novan (NOVN) +81%, Aptinyx (APTX) +25%, Vaxart (VXRT) +39%, Progenity (PROG) +28%, Chemomab Therapeutics (CMMB) +9%.Losers: Orphazyme (ORPH) -41%, Curis (CRIS) -32%, Aptose Biosciences (APTO) -30%, Galecto (GLTO) -22%,&...
primeimages/E+ via Getty Images Tesla (TSLA) was in the spotlight Friday following the formal launch of its latest electric car model. At the same time, a handful of stocks posted big premarket moves as a result of drug development news. This included Noven (NOVN), Precigen (PGEN), and Vertex...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, investors! We’re approaching the end of trading for the week but we’ve got one more day of market coverage to bring you. Of course, we’re starting that off with a look at the biggest pre-m...
JuSun/iStock via Getty Images Novan (NOVN) has climbed ~23.6% in the pre-market after announcing positive topline data from its B-SIMPLE4 pivotal Phase 3 clinical study of SB206 in patients with molluscum contagiosum (“molluscum”), a contagious skin infection caused by the ...
– B-SIMPLE4 achieves statistical significance for the primary endpoint with p-value less than 0.0001 – – No serious adverse events related to treatment with SB206 – – Novan intends to submit New Drug Application (“NDA”) no...
loops7/E+ via Getty Images Novan (NOVN) has added ~5.5% in early hours after announcing positive preclinical results for the company’s NITRICIL platform technology, berdazimer sodium (NVN1000) in a SARS-CoV-2 transmission model in golden Syrian hamsters. In the study, a ...
News, Short Squeeze, Breakout and More Instantly...
– The Company and Ligand Pharmaceuticals sign agreement to sell substantially all of Novan’s assets under Section 363 of the U.S. Bankruptcy Code, along with a commitment from Ligand to fund $15 million in debtor-in-possession financing – – Progression toward...
DURHAM, N.C., June 05, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will host a live audio webcast of the Company’s 2023 Annual Meeting of Stockholders (“ASM”) being held on Tuesday, June 6...
– Company directing resources on the potential approval of berdazimer gel, 10.3% (SB206) for molluscum contagiosum – – Process to explore a sale or out-license of commercial assets or other business transaction continues – – Continued progress ...